Respirable bacteriophages for the treatment of bacterial lung infections

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 26, Issue 6, 2013, Pages 317-335

  Hoe, Susan ^a   Semler, Diana D ^a   Goudie, Amanda D ^a   Lynch, Karlene H ^a   Matinkhoo, Sadaf ^a   Finlay, Warren H ^a   Dennis, Jonathan J ^a   Vehring, Reinhard ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Antibiotic resistance; Bacterial lung infections; Bacteriophages; Phage therapy; Respiratory drug delivery

Indexed keywords

ANTIBIOTIC AGENT; BACTERIOPHAGE DNA; CHOLERA TOXIN; ENDOTOXIN; HYDROXYPROPYLMETHYLCELLULOSE; HYPOTONIC SOLUTION; LACTOFERRIN; LIPOPOLYSACCHARIDE; MICROBIAL PRODUCTS NOT CLASSIFIED ELSEWHERE; VIRULENCE FACTOR; VIRUS VACCINE;

AEROSOL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL CELL; BACTERIAL INFECTION; BACTERIAL LOAD; BACTERIAL VIRULENCE; BACTERIOPHAGE; BRONCHIECTASIS; BRONCHOPNEUMONIA; BURN; BURN INFECTION; CHRONIC BRONCHITIS; CLOSTRIDIUM DIFFICILE; DEVICE SAFETY; DRUG EFFICACY; DRUG SAFETY; DRY POWDER INHALER; ENZYME ACTIVITY; ESCHERICHIA COLI; EXPERIMENTAL THERAPY; FREEZE DRYING; HOST CELL; HUMAN; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNOSTIMULATION; IONIC STRENGTH; KLEBSIELLA; LARYNGITIS; LUNG INFECTION; MEMBRANE FILTER; META ANALYSIS; METERED DOSE INHALER; NEBULIZATION; NEBULIZER; NONHUMAN; PARTICLE SIZE; PH; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLEURISY; PROTEUS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; PSEUDOMONAS PHAGE; RESPIRATORY THERAPEUTIC DEVICE; REVIEW; RHINITIS; SHEAR STRESS; SHELF LIFE; SPRAY DRYING; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STAPHYLOCOCCUS PHAGE; STORAGE; STREPTOCOCCUS; STREPTOCOCCUS PHAGE; SUSPENSION; TEMPERATURE STRESS; THERAPY EFFECT; VIBRIO CHOLERAE; VIRION;

ADMINISTRATION, INHALATION; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BACTERIOPHAGES; BIOLOGICAL THERAPY; DRUG RESISTANCE, BACTERIAL; HUMANS; LUNG; RESPIRATORY TRACT INFECTIONS; VIRULENCE;

EID: 84888144085     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2012.1001     Document Type: Review

References (148)

1. Riley JC: Rising Life Expectancy: A Global History. Cambridge University Press, Cambridge; 2001.
2. Palumbi S: Evolution-humans as the world's greatest evolutionary force. Science. 2001;293:1786-1790. (Pubitemid 32845769)
3. Hassett DJ, Korfhagen TR, Irvin RT, Schurr MJ, Sauer K, Lau GW, Sutton MD, Yu H, and Hoiby N: Pseudomonas aeruginosa biofilm infections in cystic fibrosis: insights into pathogenic processes and treatment strategies. Expert Opin Ther Targets. 2010;14:117-130.
4. Mandsberg LF, Ciofu O, Kirkby N, Christiansen LE, Poulsen H, and Hoiby N: Antiobiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. Antimicrob Agents Chemother. 2009;53:2483-2491.
5. Seed KD, and Dennis JJ: Isolation and characterization of bacteriophages of the Burkholderia cepacia complex. FEMS Microbiol Lett. 2005;251:273-280. (Pubitemid 41383879)
6. Reinert RR: The antimicrobial resistance profile of Streptococcus pneumoniae. Clin Microbiol Infect. 2009;15:7-11.
7. Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, and Walsh TR: Characterization of a new metallo-blactamase gene, blaNDM-1, and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother. 2009;53:5046-5054.
8. Karthikeyan K, Thirunarayan M, and Krishnan P: Coexistence of blaOXA-23 with blaNDM-1 and armA in clinical isolates of Acinetobacter baumannii from India. J Antimicrob Chemother. 2010;65:2253-2254.
9. World Health Organization: Multidrug and extensively drug-resistant TB (M/XDR-TB). 2010 global report on surveillance and response. Geneva, Switzerland; 2010.
10. Jassal M, and Bishai WR: Extensively drug-resistant tuberculosis. Lancet Infect Dis. 2009;9:19-30.
11. Tomlin KL, Coll OP, and Ceri H: Interspecies biofilms of Pseudomonas aeruginosa and Burkholderia cepacia. Can J Microbiol. 2001;47:949-954. (Pubitemid 33033523)
12. Coates ARM, Halls G, and Hu Y: Novel classes of antibiotics or more of the same? Br J Pharmacol. 2011;163:184-194.
13. Abedon ST, and Thomas-Abedon C: Phage therapy pharmacology. Curr Pharm Biotechnol. 2010;11:28-47.
14. Burrowes B, Harper DR, Anderson J, McConville M, and Enright MC: Bacteriophage therapy: potential uses in the control of antibiotic-resistant pathogens. Expert Rev Anti Infect Ther. 2011;9:775-785.
15. Parisien A, Allain B, Zhang J, Mandeville R, and Lan CQ: Novel alternatives to antibiotics: bacteriophages, bacterial cell wall hydrolases, and antimicrobial peptides. J Appl Microbiol. 2008;104:1-13. (Pubitemid 350265294)
16. Merabishvili M, Pirnay J, Verbeken G, Chanishvili N, Tediashvili M, Lashkhi N, Glonti T, Krylov V, Mast J, Van Parys L, Lavigne R, Volckaert G, Mattheus W, Verween G, De Corte P, Rose T, Jennes S, Zizi M, De Vos D, and Vaneechoutte M: Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS One. 2009;4:e4944.
17. Housby JN, and Mann NH: Phage therapy. Drug Discov Today. 2009;14:536-540.
18. Hanawalt PC: Density matters: the semiconservative replication of DNA. Proc Natl Acad Sci USA. 2004;101:17889-17894. (Pubitemid 40054045)
19. Delacoste P: Considérations sur le traitement des affections respiratoires banales au moyen de bacteriophages [Considerations on the treatment of common respiratory diseases by means of bacteriophages]. Rev Med Suisse Romande. 1959;79:552-563.
20. Hoeflmayr J: Inhalationstherapie mit Bakteriophagen bei therapieresistenten Infektionen [Inhalation therapy with bacteriophages for treatment-resistant infections]. Fortschritte der biologischen Aerosol-Forschung in den Jahren 1957-1961 [Advances in Biological Aerosols Research in the Years 1957-1961]. Stuttgart, Germany; pp. 403-409, 1962.
21. Abedon ST, Kuhl SJ, Blasdel BG, and Kutter EM: Phage treatment of human infections. Bacteriophage. 2011;1: 66-85.
22. Górski A, Miedzybrodzki R, Borysowski J, Weber-Da?browska B, qobocka M, Fortuna W, Letkiewicz S, Zimecki M, and Filby G: Bacteriophage therapy for treatment of infections. Curr Opin Investig Drugs. 2009;10:766-774.
23. Kutateladze M, and Adamia R: Phage therapy experience at the Eliava Institute. Med Mal Infect. 2008;38:426-430.
24. Buckling A, and Rainey PB: Antagonistic coevolution between a bacterium and a bacteriophage. Proc R Soc Lond B. 2002;269:931-936. (Pubitemid 34518136)
25. Thiel K: Old dogma, new tricks-21st century phage therapy. Nat Biotechnol. 2004;22:31-36. (Pubitemid 38057949)
26. Abedon ST, Herschler TD, and Stopar D: Bacteriophage latent-period evolution as a response to resource availability. Appl Environ Microbiol. 2001;67:4233-4241. (Pubitemid 33641721)
27. Bade EG: Asymmetric transcription of bacteriophage Mu-1. J Virol. 1972;10:1205-1207.
28. Carlton RM: Phage therapy: past history and future prospects. Arch Immunol Ther Exp. 1999;47:267-274.
29. Hadas H, Einav M, Fishov I, and Zaritsky A: Bacteriophage T4 development depends on the physiology of its host Escherichia coli. Microbiology. 1997;143:179-185. (Pubitemid 27072973)
30. Levin BR, and Bull JJ: Population and evolutionary dynamics of phage therapy. Nat Rev Microbiol. 2004;2: 166-173. (Pubitemid 39490070)
31. Levin BR, Stewart FM, and Chao L: Resource-limited growth, competition, and predation: a model and experimental studies with bacteria and bacteriophage. Am Nat. 1977;111:3-24.
32. Wolfson J, Dressler D, and Magazin M: Bacteriophage T7 DNA replication: a linear replicating intermediate. Proc Natl Acad Sci USA. 1972;69:499-504.
33. Labrie SJ, Samson JE, and Moineau S: Bacteriophage resistance mechanisms. Nat Rev Microbiol. 2010;8:317-327.
34. Kelly D, McAuliffe O, Ross RP, O'Mahony J, and Coffey A: Development of a broad-host-range phage cocktail for biocontrol. Bioeng Bugs. 2011;2:31-37.
35. Pouillot F, Bois H, and Iris F: Genetically engineered virulent phage banks in the detection and control of emergent pathogenic bacteria. Biosecur Bioterror. 2010;8:155-169.
36. Coutinho HDM, Falcao-Silva VS, and Goncalves GF: Pulmonary bacterial pathogens in cystic fibrosis patients and antibiotic therapy: a tool for the health workers. Int Arch Med. 2008;1:24.
37. Campbell A: The future of bacteriophage biology. Nat Rev Genet. 2003;4:471-477. (Pubitemid 36648146)
38. Oppenheim AB, Kobiler O, Stavans J, Court DL, and Adhya S: Switches in bacteriophage lambda development. Annu Rev Genet. 2005;39:409-429. (Pubitemid 43011121)
39. Boyd EF, and Brüssow H: Common themes among bacteriophage-encoded virulence factors and diversity among the bacteriophages involved. Trends Microbiol. 2002;10: 521-529. (Pubitemid 35284799)
40. Karaolis DKR, Somara S, Maneval DR, Johnson JA, and Kaper JB: A bacteriophage encoding a pathogenicity island, a type-IV pilus and a phage receptor in cholera bacteria. Nature. 1999;399:375-379. (Pubitemid 29318137)
41. Waldor MK, and Mekalanos JJ: Lysogenic conversion by a filamentous phage encoding cholera toxin. Science. 1996; 272:1910-1913. (Pubitemid 26234495)
42. Griffiths AJF, Miller JH, Suzuki DT, Lewontin RC, and Gelbart WM: An Introduction to Genetic Analysis, 7th ed. W.H. Freeman and Company, New York, NY; pp. 229-230, 348-350, 2000.
43. Gill JJ, Summer EJ, Russell WK, Cologna SM, Carlile TM, Fuller AC, Kitsopoulos K, Mebane LM, Parkinson BN, Sullivan D, Carmody LA, Gonzalez CF, LiPuma JJ, and Young R: Genomes and characterization of phages Bcep22 and BcepIL02, founders of a novel phage type in Burkholderia cenocepacia. J Bacteriol. 2011;193: 5300-5313.
44. Lynch KH, Stothard P, and Dennis JJ: Characterization of DC1, a broad/host/range Bcep22-like podovirus. Appl Environ Microbiol. 2012;78:889-891.
45. Lynch KH, and Dennis JJ: Genomic analysis and modification of Burkholderia cepacia complex bacteriophages: Cangene Gold Medal Lecture. Can J Microbiol. 2012;58: 221-235.
46. Meader E, Mayer MJ, Gasson MJ, Steverding D, Carding SR, and Narbad A: Bacteriophage treatment significantly reduces viable Clostridium difficile and prevents toxin production in an in vitro model system. Anaerobe. 2010;16:549-554.
47. Carmody LA, Gill JJ, Summer EJ, Sajjan US, Gonzalez CF, Young RF, and LiPuma JJ: Efficacy of bacteriophage therapy in a model of Burkholderia cenocepacia pulmonary infection. J Infect Dis. 2010;201:264-271.
48. Lynch KH, Seed KD, Stothard P, and Dennis JJ: Inactivation of Burkholderia cepacia complex phage KS9 gp41 identifies the phage repressor and generates lytic virions. J Virol. 2010;84:1276-1288.
49. Ramesh V, Fralick JA, and Rolfe RD: Prevention of Clostridium difficile-induced ileocecitis with bacteriophage. Anaerobe. 1999;5:69-78. (Pubitemid 29431598)
50. Seed KD, and Dennis JJ: Experimental bacteriophage therapy increases survival of Galleria mellonella larvae infected with clinically relevant strains of the Burkholderia cepacia complex. Antimicrob Agents Chemother. 2009;53: 2205-2208.
51. Capparelli R, Parlato M, Borriello G, Salvatore P, and Iannelli D: Experimental phage therapy against Staphylococcus aureus in mice. Antimicrob Agents Chemother. 2007;51:2765-2773. (Pubitemid 47206211)
52. Matsuzaki S, Yasuda M, Nishikawa H, Kuroda M, Ujihara T, Shuin T, Shen Y, Jin Z, Fujimoto S, Nasimuzzaman MD, Wakiguchi H, Sugihara S, Sugiura T, Koda S, Muraoka A, and Imai S: Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage jMR11. J Infect Dis. 2003;187:613-624. (Pubitemid 36250025)
53. Paul VD, Sundarrajan S, Rajagopalan SS, Hariharan S, Kempashanaiah N, Padmanabhan S, Sriram B, and Ramachandran J: Lysis-deficient phages as novel therapeutic agents for controlling bacterial infection. BMC Microbiol. 2011;11:195.
54. Merril CR, Biswas B, Carlton R, Jensen NC, Creed GJ, Zullo S, and Adhya S: Long-circulating bacteriophage as antibacterial agents. Proc Natl Acad Sci USA. 1996;93:3188-3192. (Pubitemid 26125592)
55. Rapson ME, Burden FA, Glancey LP, Hodgson DA, and Mann NH: Anti-bacterial agents. Patent Application 11/ 963,899, December 25, 2008.
56. Brüssow H, Canchaya C, and Hardt W: Phages and the evolution of bacterial pathogens: from genomic rearrangements to lysogenic conversion. Microbiol Mol Biol Rev. 2004;68:560-602. (Pubitemid 39238283)
57. Glonti T, Chanishvili N, and Taylor PW: Bacteriophagederived enzyme that depolymerizes the alginic acid capsule associated with cystic fibrosis isolates of Pseudomonas aeruginosa. J Appl Microbiol. 2010;108:695-702.
58. Leiman PG, Battisti AJ, Bowman VD, Stummeyer K, Mühlenhoff M, Gerardy-Schahn R, Scholl D, and Molineux IJ: The structures of bacteriophages K1E and K1-5 explain processive degradation of polysaccharide capsules and evolution of new host specificities. J Mol Biol. 2007;371: 836-849. (Pubitemid 47087828)
59. Alemayehu D, Casey PG, McAuliffe O, Guinane CM, Martin JG, Shanahan F, Coffey A, Ross RP, and Hill C: Bacteriophages jMR299-2 and jNH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells. MBio. 2012;3:e00029-e00012.
60. Lu TK, and Collins JJ: Dispersing biofilms with engineered enzymatic bacteriophage. Proc Natl Acad Sci USA. 2007; 104:11197-11202. (Pubitemid 47175118)
61. Moradpour Z, and Ghasemian A: Modified phages: novel antimicrobial agents to combat infectious diseases. Biotechnol Adv. 2011;29:732-738.
62. Mahichi F, Synnott AJ, Yamamichi K, Osada T, and Tanji Y: Site-specific recombination of T2 phage using IP008 long tail fiber genes provides a targeted method for expanding host range while retaining lytic activity. FEMS Microbiol Lett. 2009;295:211-217.
63. Hagens S, and Bläsi U: Genetically modified filamentous phage as bactericidal agents: a pilot study. Lett Appl Microbiol. 2003;37:318-323. (Pubitemid 37186625)
64. Hagens S, Habel A, von Ahsen U, von Gabain A, and Bläsi U: Therapy of experimental Pseudomonas infections with a nonreplicating genetically modified phage. Antimicrob Agents Chemother. 2004;48:3817-3822. (Pubitemid 39304609)
65. Westwater C, Kasman LM, Schofield DA,Werner PA, Dolan JW, Schmidt MG, and Norris JS: Use of genetically engineered phage to deliver antimicrobial agents to bacteria: an alternative therapy for treatment of bacterial infections. Antimicrob Agents Chemother. 2003;47:1301-1307. (Pubitemid 36368589)
66. Lu TK, and Collins JJ: Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy. Proc Natl Acad Sci USA. 2009;106:4629-4634.
67. Uchiyama J, Maeda Y, Takemura I, Chess-Williams R, Wakiguchi H, and Matsuzaki S: Blood kinetics of four intraperitoneally administered therapeutic candidate bacteriophages in healthy and neutropenic mice. Microbiol Immunol. 2009;53:301-304.
68. Reyes A, Semenkovich NP, Whiteson K, Rohwer F, and Gordon JI: Going viral: next-generation sequencing applied to phage populations in the human gut. Nat Rev Microbiol. 2012;10:607-617.
69. Wright A, Hawkins CH, Änggard EE, and Harper DR: A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol. 2009;34:349-357.
70. Kutter E, De Vos D, Gvasalia G, Alavidze Z, Gogokhia L, Kuhl S, and Abedon ST: Phage therapy in clinical practice: treatment of human infections. Curr Pharm Biotechnol. 2010;11:69-86.
71. Sulakvelidze A, and Barrow P. Phage therapy in animals and agribusiness. In: E Kutter and A Sulakvelidze, (eds). Bacteriophages: Biology and Application. CRC Press, Boca Raton, FL; pp. 335-380, 2005.
72. Gill JJ, and Hyman P: Phage choice, isolation, and preparation for phage therapy. Curr Pharm Biotechnol. 2010;11:2-14.
73. Lenherr H, and Bartsch R: Process and system for the industrial scale purification of bacteriophages intended for bacteriophage therapy. Patent Application 2011/0281329 A1, November 17, 2011.
74. Soothill J, Hawkins C, and Harper D: Bacteriophage-containing therapeutic agents. Patent Patent 7,807,149 B2, October 5, 2010.
75. Skurnik M, Pajunen M, and Kiljunen S: Biotechnological challenges of phage therapy. Biotechnol Lett. 2007;29:995-1003. (Pubitemid 46800624)
76. Boratynski J, Syper D, Weber-Da?browska B, qusiak-Szelachowska M, Pozniak G, and Górski A: Preparation of endotoxin-free bacteriophages. Cell Mol Biol Lett. 2004;9: 253-259. (Pubitemid 38902220)
77. Wei GL, Liu XL, Li JH, Liu Y, and Shang ZH: Endotoxin removal in some medicines and human serum albumin solution by affinity membranes. Sepuzhongguó huaxué hu [Chin J Chromatogr]. 2002;2:108-114.
78. Wilson MJ, Haggart CL, Gallagher SP, and Walsh D: Removal of tightly bound endotoxin from biological products. J Biotechnol. 2001;88:67-75. (Pubitemid 32480119)
79. Boratynski J, Górski A, Weber-Da?browska B, and Szermer-Olearnik B: Method of obtaining bacteriophage preparation. Patent Application 2010/0227376 A1, September 9, 2010.
80. Ulmer JB, Valley U, and Rappuoli R: Vaccine manufacturing: challenges and solutions. Nat Biotechnol. 2006;24: 1377-1383. (Pubitemid 44722101)
81. Bujanover S: Production of bacteriophage compositions for use in phage therapy. Patent 7,588,929 B2, September 25, 2009.
82. Clark WA: Comparison of several methods for preserving bacteriophages. Appl Environ Microbiol. 1962;10:466-471.
83. Mullan WMA: Preparation and storage of high titre lactococcal lysates [Web page]. 2005; Available at http://www .dairyscience.info/preparation-and- storage-of-high-titrelactococcal-lysates.html. Accessed October 31, 2011.
84. Golshahi L, Lynch KH, Dennis JJ, and Finlay WH: In vitro lung delivery of bacteriophages KS4-M and FKZ using dry powder inhalers for treatment of Burkholderia cepacia complex and Pseudomonas aeruginosa infections in cystic fibrosis. J Appl Microbiol. 2010;110:106-117.
85. JSC Biochimpharm. Our products [Web page]. 2010; Available at http://www.biochimpharm.ge/index.php?option=com-content&view= category&layout=blog&id=1&Itemid=2&lang=en. Accessed June 26, 2012.
86. Advanced Biophage Technologies. Products [Web Page]. Available at http://advancedbiophagetechnologies.com/ products.html. Accessed June 26, 2012.
87. Garca P, Madera C, Martinez B, Rodriguez A, and Evaristo Suárez J: Prevalence of bacteriophages infecting Staphylococcus aureus in dairy samples and their potential as biocontrol agents. J Dairy Sci. 2009;92:3019-3026.
88. Caldeira JC, and Peabody DS: Thermal stability of RNA phage virus-like particles displaying foreign peptides. J Nanobiotechnol. 2011;9:22.
89. Briers Y, Miroshnikov K, Chertkov O, Nekrasov A, Mesyanzhinov V, Volckaert G, and Lavigne R: The structural peptidoglycan hydrolase gp181 of bacteriophage jKZ. Biochem Biophys Res Commun. 2008;374:747-751.
90. Muller-Merbach M, Neve H, and Hinrichs J: Kinetics of the thermal inactivation of the Lactococcus lactis bacteriophage P008. J Dairy Res. 2005;72:281-286. (Pubitemid 41323109)
91. Atamer Z, and Hinrichs J: Thermal inactivation of the heatresistant Lactococcus lactis bacteriophage P680 in modern cheese processing. Int Dairy J. 2010;20:163-168.
92. Knezevic P, Obreht D, Curcin S, Petrusic V, Kostansjek, and Petrovic O: Phages of Pseudomonas aeruginosa: response to environmental factors and in vitro ability to inhibit bacterial growth and biofilm formation. J Appl Microbiol. 2011;111: 245-254.
93. Chi EY, Krishnan S, Randolph TW, and Carpenter JF: Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation. Pharm Res. 2003;20:1325-1336. (Pubitemid 37164039)
94. Langlet J, Gaboriaud F, and Gantzer C: Effects of pH on plaque forming unit counts and aggregation of MS2 bacteriophage. J Appl Microbiol. 2007;103:1632-1638. (Pubitemid 47620558)
95. Furiga A, Pierre G, Glories M, Aimar P, Roques C, Causserand C, and Berge M: Effects of ionic strength on bacteriophage MS2 behavior and their implications for the assessment of virus retention by ultrafiltration membranes. Appl Environ Microbiol. 2011;77:229-236.
96. Golshahi L, Seed KD, Dennis JJ, and Finlay WH: Toward modern inhalational bacteriophage therapy: nebulisation of bacteriophages of Burkholderia cepacia complex. J Aerosol Med Pulm Drug Deliv. 2008;21:351-359.
97. Manning MC, Chou DK, Murphy BM, Payne RW, and Katayama DS: Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27:544-575.
98. Branston S, Stanley E,Ward J, and Keshavarz-Moore E: Study of robustness of filamentous bacteriophages for industrial applications. Biotechnol Bioeng. 2011;108:1468-1472.
99. Jaafar-Maalej C, Andrieu V, Elaissari A, and Fessi H: Assessment methods of inhaled aerosols: technical aspects and applications. Expert Opin Drug Deliv. 2009;6:941-959.
100. Finlay WH: Mechanics of Inhaled Pharmaceutical Aerosols: An Introduction. Academic Press, San Diego, CA; 2001.
101. Eichinger M, Heussel CP, Kauczor HU, Tiddens H, and Puderbach M: Computed tomography and magnetic resonance imaging in cystic fibrosis lung disease. J Magn Reson Imaging. 2010;32:1370-1378.
102. Kaza V, Katz MF, Cumming S, Frost AE, and Safdar Z: Correlation of chest radiograph pattern with genotype, age, and gender in adult cystic fibrosis. Chest. 2007;132:569-574. (Pubitemid 47282390)
103. Davis SD, Fordham LA, Brody AS, Noah TL, Retsch-Bogart GZ, Qaqish BF, Yankaskas BC, Johnson RC, and Leigh MW: Computed tomography reflects lower airway inflammation and tracks changes in early cystic fibrosis. Am J Respir Crit Care. 2007;175:943-950. (Pubitemid 46684705)
104. Brody AS, Klein JS, Molina PL, Quan J, Bean JA, and Wilmott RW: High-resolution computed tomography in young patients with cystic fibrosis: distribution of abnormalities and correlation with pulmonary function tests. J Pediatr. 2004;145:32-38. (Pubitemid 38962449)
105. Brown JS, and Bennett WD: Deposition of coarse particles in cystic fibrosis: model predictions versus experimental results. J Aerosol Med. 2004;17:239-248. (Pubitemid 39299325)
106. Morello E, Saussereau E, Maura D, Huerre M, Touqui L, and Debarbieux L: Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fibrosis strains: first steps towards treatment and prevention. PLoS One. 2011;6: e16963.
107. Slopek S, Weber-Dabrowska B, Dabrowski M, and Kucharewicz-Krukowska A: Results of bacteriophage treatment of suppurative bacterial infections in the years 1981-1986. Arch Immunol Ther Exp. 1987;35:569-583.
108. Finlay WH: Pharmaceutical aerosol sprays for drug delivery to the lungs. In: N Ashgriz, (ed). Handbook of Atomization and Sprays: Theory and Applications. Springer, Boston, MA; pp. 899-908, 2011.
109. Knoch M, and Finlay WH: Nebulizer technologies. In: MJ Rathbone, J Hadgraft, MS Roberts, and ME Lane, (eds). Modified-Release Drug Delivery Technology, 2nd ed. Informa Healthcare, New York, NY; pp. 613-622, 2008.
110. Eslamian M, and Ashgriz N: Swirl, T-jet and vibratingmesh atomizers. In: N Ashgriz, (ed). Handbook of Atomization and Sprays: Theory and Applications. Springer Press, Boston, MA; pp. 755-773, 2011.
111. Xu Z, and Hickey AJ: The physics of aerosol droplet and particle generation from inhalers. In: HDC Smyth and AJ Hickey, (eds). Controlled Pulmonary Drug Delivery. Springer, New York, NY; 75-100, 2011.
112. Baazy A, Toivola M, Adhikari A, Sivasubramani SK, Reponen T, and Grinshpun SA: Do N95 respirators provide 95% protection level against airborne viruses, and how adequate are surgical masks? Am J Infect Control. 2006;34:51-57. (Pubitemid 43254570)
113. Eninger RM, Hogan CJ, Biswas P, Ashikari A, Reponen T, and Grinshpun SA: Electrospray versus nebulization for aerosolization and filter testing with bacteriophage particles. Aerosol Sci Technol. 2009;43:298-304.
114. Liu K, Wen Z, Li N, Yang W, Wang J, Hu L, Dong X, Lu J, and Li J: Impact of relative humidity and collection media on mycobacteriophage D29 aerosol. Appl Environ Microbiol. 2012;78:1466-1472.
115. Lass JS, Sant A, and Knoch M: New advances in aerosolised drug delivery: vibrating membrane nebuliser technology. Expert Opin Drug Deliv. 2006;3:693-702. (Pubitemid 44383495)
116. Nichols MEK, Stanislaus T, Keshavarz-Moore E, and Young HA: Disruption of leaves and initial extraction of wildtype CPMV virus as a basis for producing vaccines from plants. J Biotechnol. 2002;92:229-235. (Pubitemid 33022627)
117. Sotome I, Nei D, Tsuda M, Hossen MS, Takenaka M, Okadome H, and Isobe S: Decontamination effect of milling by a jet mill on bacteria in rice flour. Biocontrol Sci. 2011;16:79-83.
118. Schwegman JJ, Hardwick LM, and Akers MJ: Practical formulation and process development of freeze-dried products. Pharm Dev Technol. 2005;10:151-173. (Pubitemid 40677436)
119. Jonczyk E, Klak M, Miedzybrodzki R, and Górski A: The influence of external factors on bacteriophages. Folia Microbiol (Praha). 2011;56:191-200.
120. Schade AL, and Caroline L: The preparation of a polyvalent dysentery bacteriophage in a dry and stable form: I. Preliminary investigations and general procedures. J Bacteriol. 1943;45:463-473.
121. Schade AL, and Caroline L: The preparation of a polyvalent dysentery bacteriophage in a dry and stable form: III. Stability of the dried bacteriophage towards heat, humidity, age and acidity. J Bacteriol. 1944;48:243-251.
122. Liu J: Physical characterization of pharmaceutical formulations in frozen and freeze-dried solid states: techniques and applications in freeze-drying development. Pharm Dev Technol. 2006;11:3-28.
123. Puapermoonsiri U, Spencer J, and van der Walle CF: A freeze-dried formulation of bacteriophage encapsulated in biodegradable microspheres. Eur J Pharm Biopharm. 2009; 72:26-33.
124. Finlay WH, Dennis JJ, Orszanska H, Seed KD, and Lynch KH: Bacteriophage compositions for treatment of bacterial infections. Patent Application 20110293671 A1, December 1, 2011.
125. Wang ZL, Finlay WH, Peppler MS, and Sweeney LG: Powder formation by atmospheric spray-freeze drying. Powder Tech. 2006;170:45-52. (Pubitemid 44715974)
126. Ammons MCB, Ward LS, Dowd S, and James GA: Combined treatment of Pseudomonas aeruginosa biofilm with lactoferrin and xylitol inhibits the ability of bacteria to respond to damage resulting from lactoferrin iron chelation. Int J Antimicrob Agents. 2011;37:316-323.
127. Singh PK: Iron sequestration by human lactoferrin stimulates P. aeruginosa surface motility and blocks biofilm formation. Biometals. 2004;17:267-270. (Pubitemid 38987148)
128. Alfadhel M, Puapermpoonsiri U, Ford SJ, McInnes FJ, and van der Walle CF: Lyophilised inserts for nasal administration harboring bacteriophage selective for Staphylococcus aureus: in vitro evaluation. Int J Pharm. 2011;416: 280-287.
129. Vehring R: Expert review: Pharmaceutical particle engineering via spray drying. Pharm Res. 2008;25:999-1022.
130. Boraey MA, Matinkhoo S, and Vehring R: A new time and cost effective approach for the development of microparticles for pulmonary drug delivery. [Abstract] Presented at Respiratory Drug Delivery Europe, Berlin, Germany, May 3-8, 2011; Vol. 2, pp. 473-477.
131. Ivey J, and Vehring R: The use of modeling in spray drying of emulsions and suspensions accelerates formulation and process development. Comput Chem Eng. 2010;34:1036-1040.
132. Peighambardoust SH, Golshan Tafti A, and Hesari J: Application of spray drying for preservation of lactic acid starter cultures: a review. Trends Food Sci Technol. 2011; 22:215-224.
133. Burger JL, Cape SP, Braun CS, McAdams DH, Best JA, Bhagwat P, Pathak P, Rebits LG, and Sievers RE: Stabilizing formulations for inhalable powders of live-attenuated measles virus vaccine. J Aerosol Med Pulm Drug Deliv. 2008;21:25-34.
134. Feng AL, Boraey MA, Gwin MA, Finlay PR, Kuehl PJ, and Vehring R: Mechanistic models facilitate efficient development of leucine containing microparticles for pulmonary drug delivery. Int J Pharm. 2011;409:156-163.
135. Ohtake S, Martin RA, Yee L, Chen DX, Kristensen DD, Lechuga-Ballesteros D, and Truong-Le V: Heat-stable measles vaccine produced by spray drying. Vaccine. 2010; 28:1275-1284.
136. Walbeck AK: Methods for drying bacteriophage and bacteriophage containing compositions, the resulting dry compositions, and methods of use. Patent Application 2009/0093041 A1, April 9, 2009.
137. Matinkhoo S, Lynch KH, Dennis JJ, Finlay WH, and Vehring R: Spray-dried respirable powders containing bacteriophages for the treatment of pulmonary infections. J Pharm Sci. 2011;100:5197-5205.
138. Debarbieux L, Leduc D, Maura D, Morello E, Criscuolo A, Grossi O, Balloy V, and Touqui L: Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections. J Infect Dis. 2010;201:1096-1104.
139. Halperin S, Heifetz S, and Kasina A: Experimental respiratory infection with Bordetella pertussis in mice: comparison of two methods. Clin Invest Med. 1988;11:297-303.
140. Kvachadze L, Balarjishvili N, Meskhi T, Tevdoradze E, Skhirtladze N, Pataridze T, Adamia R, Topuria T, Kutter E, Rhode C, and Kutateladze M: Evaluation of lytic activity of staphylococcal bacteriophage Sb-1 against freshly isolated clinical pathogens. Microb Biotechnol. 2011;4:643-650.
141. Bruttin A, and Brüssow H: Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob Agents Chemother. 2005;49:2874-2878. (Pubitemid 40917605)
142. Rhoads DD, Wolcott RD, Kuskowski MA, Wolcott BM, Ward LS, and Sulakvelidze A: Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. J Wound Care. 2009;18:240-243.
143. Payne RJH, and Jansen VAA: Pharmacokinetic principles of bacteriophage therapy. Clin Pharmacokinet. 2003;42: 315-325. (Pubitemid 36433874)
144. Verbeken G, Pirnaym JP, De Vos D, Jennes S, Zizi M, Lavigne R, Casteels M, and Huys I: Optimizing the European regulatory framework for sustainable bacteriophage therapy in human medicine. Arch Immunol Ther Exp (Warsz). 2012;60:161-172.
145. Chanishvili N, Chanishvili T, Tediashvili M, and Barrow PA: Phages and their application against drug-resistant bacteria. J Chem Technol Biotechnol. 2001;76:689-699. (Pubitemid 32640402)
146. Sulakvelidze A, Alavidze Z, and Glenn Morris Jr. J: Bacteriophage therapy. Antimicrob Agents Chemother. 2001; 45:649-659. (Pubitemid 32182003)
147. Weber-Da?browska B, Mulczyk M, Górski A, Boratynski J, Kusiak-Szelachowska M, and Syper D: Methods of polyvalent bacteriophage preparation for the treatment of bacterial infections. Patent US 7, 232, 564 B2. june 19, 2007.
148. Garca P, Madeia C, Martnez B, Rodrguez A, and Evaristo Suárez J: Prevalence of bacteriophages infecting Staphylococcus aureus in dairy samples and their potential as biocontrol agents. J Dairy Sci. 2009;92:3019-3026.